Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study.
Thea H WikenMarte L HøivikKaroline AnisdahlLydia C T BuerDavid J WarrenNils BolstadMilada Cvancarova Småstuen HagenBjørn A MoumAsle Wilhelm MedhusPublished in: Crohn's & colitis 360 (2024)
Three of the four patients remained on subcutaneous vedolizumab after 18 months, a large proportion received treatment at standard dosing intervals, and disease activity remained stable. This indicates that switching from intravenous to subcutaneous vedolizumab treatment is convenient and safe.